Indicators for QUM in Australian Hospitals
Quicklinks
 |
- Manual of Indicators
- Antithrombotic therapy
- Antibiotic therapy
- Medication ordering
- Pain management
- Continuity of care
- Hospital wide medication management policies
Manual of Indicators
Sections of the Manual
- Introduction (655KB)
Includes: Foreword; Introduction to NSW TAG and CEC; Acknowledgements; Background; Developing the indicators; Using the indicators; Indicator summary; Indicator format and References. - Appendix (53KB)
Individual Indicators
- 1.1 Percentage of admitted adult patients that are assessed for risk of venous thromboembolism
- 1.2 Percentage of patients at high risk of venous thromboembolism that receive appropriate prophylaxis
- 1.3 Percentage of patients prescribed enoxaparin whose dosing schedule is appropriate
- 1.4 Percentage of patients prescribed hospital initiated warfarin whose loading doses are consistent with a Drug and Therapeutics Committee approved protocol
- 1.5 Percentage of patients with an INR above 4 whose dosage has been adjusted or reviewed prior to the next warfarin dose
- 1.6 Percentage of patients with atrial fibrillation that are discharged on warfarin
- 2.1 Percentage of patients undergoing specified surgical procedures that receive an appropriate prophylactic antibiotic regimen
- 2.2 Percentage of prescriptions for restricted antibiotics that are concordant with Drug and Therapeutics Committee approved criteria
- 2.3 Percentage of patients with a toxic or sub-therapeutic aminoglycoside concentration whose dosage has been adjusted or reviewed prior to the next aminoglycoside dose
- 2.4 Percentage of adult patients with community acquired pneumonia that are assessed using an appropriate validated objective measure of pneumonia severity
- 2.5 Percentage of patients presenting with community acquired pneumonia that are prescribed guideline concordant antibiotic therapy
- 3.1 Percentage of patients whose current medications are documented and reconciled at admission
- 3.2 Percentage of patients whose known adverse drug reactions are documented on the current medication chart
- 3.3 Percentage of medication orders that include error-prone abbreviations
- 3.4 Percentage of paediatric medication orders that include the correct dose per kilogram (or body surface area) and a safe total dose
- 3.5 Percentage of medication orders for intermittent therapy that are prescribed safely
- 3.6 Percentage of patients receiving cytotoxic chemotherapy whose treatment is guided by a hospital approved chemotherapy treatment protocol
- 4.1 Percentage of postoperative patients whose pain intensity is documented using an appropriate validated assessment tool
- 4.2 Percentage of postoperative patients that are given a written pain management plan at discharge and a copy is communicated to the primary care clinician
- 5.1 Percentage of patients with acute coronary syndrome that are prescribed appropriate medications at discharge
- 5.2 Percentage of patients with chronic heart failure that are prescribed appropriate medications at discharge
- 5.3 Percentage of discharge summaries that include medication therapy changes and explanations for change
- 5.4 Percentage of patients discharged on warfarin that receive written information regarding warfarin management prior to discharge
- 5.5 Percentage of patients with a new adverse drug reaction (ADR) that are given written ADR information and a copy is communicated to the primary care clinician
- 5.6 Percentage of patients with asthma that are given a written asthma action plan at discharge and a copy is communicated to the primary care physician
- 5.7 Percentage of patients receiving sedatives at discharge that were not taking them at admission
Hospital wide medication management policies
- 6.1 Percentage of medication storage areas outside pharmacy where potassium ampoules are available
- 6.2 Percentage of patients that are reviewed by a clinical pharmacist within one day of admission
- 6.3 Percentage of parenteral opioid dosage units that are pethidine
- 6.4 Percentage of submissions for formulary listing of new chemical entities for which the Drug and Therapeutics Committee has access to adequate information for appropriate decision making
Back to programs and projects page
